Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
small molecules
Biotech
Novartis pays Antares $105M to tackle undruggable cancer targets
Novartis is paying Antares $105 million upfront in a deal worth up to $1.9 billion to tackle historically undruggable cancer targets.
Nick Paul Taylor
Jun 24, 2026 9:13am
Biogen inks $1B RayThera buyout to bag immunology assets
Jun 18, 2026 4:10am
Ambrosia scores $100M series B to advance next-gen oral GLP-1
Mar 31, 2026 10:02am
Amgen weaves in UK biotech with up to $840M acquisition
Jan 6, 2026 10:35am
After $4.8B Amicus buy, BioMarin drops genetic disease asset
Dec 22, 2025 11:12am
Voyager sets sail on neuro research trek with Transition Bio
Nov 10, 2025 5:23pm
